Search results
Showing 76 to 87 of 87 results for bevacizumab
Next-generation sequencing panel for solid tumour cancers in children (MIB133)
NICE has developed a medtech innovation briefing (MIB) on the next-generation sequencing panel for solid tumour cancers in children .
Discontinued [GID-TA10126]
Atezolizumab for untreated advanced renal cell carcinoma [ID1365]
Discontinued [GID-TA10338]
Sorafenib for treating advanced hepatocellular carcinoma (TA474)
Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.
Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)
This appraisal has been updated and replaced by NICE technology appraisal 214.
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701
In development [GID-TA11157] Expected publication date: TBC
Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment.
This guidance has been updated and replaced by NICE technology appraisal guidance 939.
This guidance has been updated and replaced by NICE technology appraisal guidance 946.
differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior...
Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund
A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.